Pharmacogenetics in cardiovascular disease: The challenge of moving from promise to realization: Concepts discussed at the canadian network and centre for trials internationally network conference (CANNeCTIN), June 2009

Clinical Cardiology

Volumn 37, Issue 1, 2014, Pages 48-56

  Joseph, Philip G ^a   Pare, Guillaume ^a,b,c,d   Ross, Stephanie ^a   Roberts, Robert ^b,e   Anand, Sonia S ^a,b,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Department of Pathology ^*  (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; WARFARIN;

ACUTE CORONARY SYNDROME; CANADA; CARDIOVASCULAR DISEASE; DNA POLYMORPHISM; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MYALGIA; MYOPATHY; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; RHABDOMYOLYSIS; THROMBOSIS; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; TREATMENT OUTCOME;

EID: 84892564637     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22200     Document Type: Review

References (73)

1. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001; 286: 2270-2279.
2. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med. 2005; 353: 487-497.
3. Moyer TP, O'Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009; 84: 1079-1094.
4. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352: 2285-2293.
5. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008; 358: 999-1008.
6. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360: 753-764.
7. Daly AK, King BP,. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003; 13: 247-252.
8. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353: 717-719.
9. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287: 1690-1698.
10. Kamali F, Wynne H,. Pharmacogenetics of warfarin. Annu Rev Med. 2010; 61: 63-75.
11. Sanderson S, Emery J, Higgins J,. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005; 7: 97-104.
12. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008; 111: 4106-4112.
13. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009; 5: e1000433.
14. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007; 116: 2563-2570.
15. Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012; 125: 1997-2005.
16. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009; 24: 656-664.
17. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med. 2001; 345: 494-502.
18. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011; 306: 2704-2714.
19. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010; 363: 1704-1714.
20. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367: 2100-2109.
21. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the gravitas randomized trial. JAMA. 2011; 305: 1097-1105.
22. Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (rapid gene): a prospective, randomised, proof-of-concept trial. Lancet. 2012; 379: 1705-1711.
23. Voora D, Ginsburg GS,. Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol. 2012; 60: 9-20.
24. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376: 1320-1328.
25. Taubert D, von Beckerath N, Grimberg G, et al. Impact of p-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006; 80: 486-501.
26. Rudez G, Bouman HJ, van Werkum JW, et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet. 2009; 2: 515-521.
27. Bouman HJ, van Werkum JW, Rudez G, et al. The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: a clinical follow-up. Thromb Haemost. 2012; 107: 189-191.
28. Hennekens CH, Schror K, Weisman S, et al. Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004; 110: 1706-1708.
29. Patrono C., Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003; 1: 1710-1713.
30. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336: 195-198.
31. Herrera-Galeano JE, Becker DM, Wilson AF, et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008; 28: 1484-1490.
32. Goodman T, Ferro A, Sharma P,. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008; 66: 222-232.
33. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.
34. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009; 25: 567-579.
35. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006; 119: 676-683.
36. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004; 291: 2821-2827.
37. Peters BJ, Klungel OH, de Boer A, et al. Genetic determinants of response to statins. Expert Rev Cardiovasc Ther. 2009; 7: 977-983.
38. Salazar LA, Hirata MH, Quintao ECR, Hirata RDC,. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal. 2000; 14: 125-131.
39. Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005; 5: 352-358.
40. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the framingham heart study. Atherosclerosis. 2001; 154: 529-537.
41. Wilson PW, Myers RH, Larson MG, et al. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. 1994; 272: 1666-1671.
42. Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet. 2009; 2: 173-181.
43. Hindorff LA, Lemaitre RN, Smith NL, et al. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics. 2008; 18: 677-682.
44. Peters BJ, Maitland-van der Zee AH, Stricker BH, et al. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenet Genomics. 2008; 18: 631-636.
45. Peters BJ, Rodin AS, Klungel OH, et al. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenet Genomics. 2010; 20: 766-774.
46. Iakoubova OA, Sabatine MS, Rowland CM, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008; 51: 449-455.
47. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003; 107: 2416-2421.
48. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010; 466: 707-713.
49. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008; 359: 789-799.
50. Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011; 21: 280-288.
51. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009; 54: 1609-1616.
52. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 1547-1559.
53. Cambien F., The angiotensin-converting enzyme (ACE) genetic polymorphism: its relationship with plasma ACE level and myocardial infarction. Clin Genet. 1994; 46: 94-101.
54. Arbustini E, Grasso M, Fasani R, et al. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J. 1995; 74: 584-591.
55. Winkelmann BR, Nauck M, Klein B, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk for myocardial infarction and coronary artery disease. Ann Intern Med. 1996; 125: 19-25.
56. McNamara DM, Holubkov R, Postava L, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004; 44: 2019-2026.
57. Arnett DK, Davis BR, Ford CE, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005; 111: 3374-3383.
58. Brugts JJ, Isaacs A, Boersma E, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J. 2010; 31: 1854-1864.
59. Bas M, Hoffmann TK, Tiemann B, et al. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br J Clin Pharmacol. 2010; 69: 179-186.
60. Gulec M, Caliskaner Z, Tunca Y, et al. The role of ACE gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol Immunopathol (Madr). 2008; 36: 134-140.
61. Duan QL, Nikpoor B, Dube MP, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 2005; 77: 617-626.
62. Mukae S, Aoki S, Itoh S, et al. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension. 2000; 36: 127-131.
63. Lee YJ, Tsai JC,. Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor-58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism. 2001; 50: 1346-1350.
64. Nishio K, Kashiki S, Tachibana H, et al. Angiotensin-converting enzyme and bradykinin gene polymorphisms and cough: a meta-analysis. World J Cardiol. 2011; 3: 329-336.
65. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010; 3: 21-28.
66. Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008; 52: 644-651.
67. Shin J, Lobmeyer MT, Gong Y, et al. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol. 2007; 99: 250-255.
68. Petersen M, Andersen JT, Hjelvang BR, et al. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol. 2011; 71: 556-565.
69. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006; 103: 11288-11293.
70. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008; 14: 510-517.
71. Frey UH, Kottenberg E, Kamler M, et al. Genetic interactions in the β-adrenoceptor/G-protein signal transduction pathway and survival after coronary artery bypass grafting: a pilot study. Br J Anaesth. 2011; 107: 869-878.
72. International Hap Map Project. Available at: http://hapmap.ncbi.nlm.nih. gov. Accessed April 2013.
73. 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491 (7422): 56-65.